US 11,925,676 B2
Method for treating neoplasia with an anti-CD38 antibody and an IL-15:IL-15R complex
Bai Liu, Culver City, CA (US); Peter Rhode, Culver City, CA (US); Wenxin Xu, Culver City, CA (US); and Hing C. Wong, Culver City, CA (US)
Assigned to Altor Bioscience, LLC., Culver City, CA (US)
Filed by Altor Bioscience, LLC, Culver City, CA (US)
Filed on Feb. 27, 2023, as Appl. No. 18/175,112.
Application 18/063,871 is a division of application No. 17/825,959, filed on May 26, 2022, granted, now 11,679,144.
Application 15/921,512 is a division of application No. 14/755,989, filed on Jun. 30, 2015, granted, now 9,925,247, issued on Mar. 27, 2018.
Application 18/175,112 is a continuation of application No. 18/063,871, filed on Dec. 9, 2022.
Application 17/825,959 is a continuation of application No. 16/925,138, filed on Jul. 9, 2020, granted, now 11,471,511, issued on Oct. 18, 2022.
Application 16/925,138 is a continuation of application No. 16/444,807, filed on Jun. 18, 2019, granted, now 11,173,191, issued on Nov. 16, 2021.
Application 16/444,807 is a continuation of application No. 15/921,512, filed on Mar. 14, 2018, granted, now 10,537,615, issued on Jan. 21, 2020.
Claims priority of provisional application 62/018,899, filed on Jun. 30, 2014.
Prior Publication US 2023/0233649 A1, Jul. 27, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 38/17 (2006.01); A61K 38/20 (2006.01); A61K 47/64 (2017.01); A61P 35/00 (2006.01); A61K 39/04 (2006.01); C07K 14/35 (2006.01); C07K 14/54 (2006.01); C07K 14/715 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01)
CPC A61K 38/2086 (2013.01) [A61K 38/1793 (2013.01); A61K 39/39558 (2013.01); A61K 47/6425 (2017.08); A61P 35/00 (2018.01); A61K 39/04 (2013.01); C07K 14/35 (2013.01); C07K 14/5443 (2013.01); C07K 14/7155 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/2887 (2013.01); C07K 16/2896 (2013.01); C07K 16/32 (2013.01); C07K 2317/732 (2013.01); C07K 2319/30 (2013.01); C07K 2319/32 (2013.01)] 23 Claims
 
1. A method for treating a neoplasia. in a subject, the method comprising: administering to said subject an effective amount of an isolated anti-CD38 antibody and an effective amount of a pharmaceutical composition comprising an IL-15:IL-15RαSu complex, wherein the effective amount of the IL-15:IL-15RαSu complex is between 0.1 μg/kg and 100 mg/kg, thereby treating the neoplasia.